Browsing Tag
STARGLO
2 posts
Genentech’s Columvi combo fails to secure FDA approval for second-line DLBCL use
FDA rejects Genentech’s sBLA for Columvi-GemOx in second-line DLBCL treatment; survival benefit data deemed insufficient for U.S. approval.
Genentech faces FDA setback for Columvi GemOx in second-line diffuse large B-cell lymphoma as SKYGLO trial becomes key to future U.S. expansion
Genentech’s Columvi GemOx sBLA faces FDA rejection in second-line DLBCL. Analysts await SKYGLO trial data for U.S. approval prospects. Learn more.